Zobrazeno 1 - 10
of 46
pro vyhledávání: '"R. Faraawi"'
Autor:
Boulos Haraoui, J. Kelsall, E.C. Keystone, Proton Rahman, P. Baer, Andrew Chow, Carter Thorne, Allen J. Lehman, Wojciech P. Olszynski, R. Faraawi, Denis Choquette, Francois Nantel, Emmanouil Rampakakis
Publikováno v:
BMC Rheumatology
BMC Rheumatology, Vol 4, Iss 1, Pp 1-14 (2020)
BMC Rheumatology, Vol 4, Iss 1, Pp 1-14 (2020)
Background Long-term clinical registries are essential tools to evaluate new therapies in a patient population that differs from those in randomized clinical trials. The objectives are to describe the profile of rheumatoid arthritis (RA) patients tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d14a69990776a53c32b7b347738fc45d
https://doi.org/10.21203/rs.2.24628/v1
https://doi.org/10.21203/rs.2.24628/v1
Autor:
Milton Baker, Larissa Lisnevskaia, Wojciech P. Olszynski, Proton Rahman, Francois Nantel, Jodie Reis, Allen J. Lehman, Odalis Asin Miilan, R. Faraawi, Meagan Rachich, Denis Choquette, P. Baer, Keltie Anderson, Raman Rai, Louis Bessette, J. Kelsall, E. Rampakakis
Publikováno v:
Poster Presentations.
Background Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. Objectives To describe the profile of rheumatoid arthritis (RA) patients treated with infl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fca70717d46d22f75e53611c46075358
https://doi.org/10.1136/annrheumdis-2019-eular.1460
https://doi.org/10.1136/annrheumdis-2019-eular.1460
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrew Chow, E. Rampakakis, R. Faraawi, O. Asin-Milan, Wojciech P. Olszynski, Proton Rahman, Allen J. Lehman, Denis Choquette, B. Osborne, Francois Nantel
Publikováno v:
Rheumatoid arthritis – biological DMARDs.
Background The Biologic Trial Registry Across Canada (BioTRAC) was a multi-centre, prospective, longitudinal, observational program that gathered and analysed data on inflammatory arthritis patients treated with infliximab (IFX), golimumab and usteki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::568b817e6d68b68789da97d7da8f1b94
https://doi.org/10.1136/annrheumdis-2018-eular.4644
https://doi.org/10.1136/annrheumdis-2018-eular.4644
Autor:
Jonathan D. Adachi, Michael F.J. O’Mahony, Carol Yacik, Judith K. Evans, Rachid Massaad, R. Faraawi, Arun Nayar
Publikováno v:
Clinical Therapeutics. 31:1747-1753
Background : The dissolution profiles of generic oral bisphosphonate alendronate (ALN) sodium for the treatment of postmenopausal osteoporosis differ by formulation, suggesting potential differences in the risk for upper gastrointestinal (GI) irritat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::149841aaa3d51fd0b8c03e12e2e2e922
https://doi.org/10.1016/j.clinthera.2009.08.016
https://doi.org/10.1016/j.clinthera.2009.08.016
Publikováno v:
The Journal of rheumatology. 42(7)
Objective.Infliximab (IFX) is a therapeutic monoclonal antibody targeting tumor necrosis factor-α indicated in the treatment of chronic inflammatory diseases. IFX is administered by intravenous infusion and may be associated with different types of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0ab16405b743fe352a1f1816f61cd9d
https://pubmed.ncbi.nlm.nih.gov/26077415
https://pubmed.ncbi.nlm.nih.gov/26077415
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Allen J. Lehman, B. Osborne, E.C. Keystone, Boulos Haraoui, K. Maslova, Francois Nantel, P. Baer, J. Sampalis, E. Rampakakis, M. Baker, Wojciech P. Olszynski, R. Faraawi, William G. Bensen, C. Tkaczyk
Publikováno v:
Annals of the Rheumatic Diseases. 75:491.3-492
Background Despite the well documented effectiveness of anti-TNF treatment in rheumatoid arthritis (RA), some patients can be refractory to treatment (primary [1ry] failure) or may lose responsiveness (secondary [2ry] failure). In such cases, switchi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::845ef9b62d0a693d8ebdb0eccc262fa4
https://doi.org/10.1136/annrheumdis-2016-eular.3766
https://doi.org/10.1136/annrheumdis-2016-eular.3766
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrew Chow, M. Baker, S. Otawa, Francois Nantel, William G. Bensen, John S. Sampalis, R. Faraawi, C. Tkaczyk, Michel Zummer, Proton Rahman, Allen J. Lehman, M. Khraishi, D. Sholter, J. Vaillancourt, Wojciech P. Olszynski, May Shawi
Publikováno v:
Annals of the Rheumatic Diseases. 74:498.2-498
Background Despite the importance of the Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in assessing patient-reported functional status and disease activity, they have been critiqued for being ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af89564283b06e90925cee439571e949
https://doi.org/10.1136/annrheumdis-2015-eular.2821
https://doi.org/10.1136/annrheumdis-2015-eular.2821